Member Info for Laura2022

There’s a lot on radio 4 lately about controlling accurate drug dose for cancer therapies.

Exactly Newuncle

PYC don't taketh risk on drugs, they are a A.I support service to save drug companies..PYC are now helping with LEAD COMPUNDS for major companies etc Cellcentric ,Bicycle,Merck

More interest

PYC and POS shows what can happen with undervalued smaller companies

Their technology can save companies $$mlns in getting drugs from phase 1 to full FDA approval

And new FDA guidelines says companies MUST use A.i/ mathematical modelling/ machine learning BEFORE FDA will consider granting drug status

I have been fortunate (and patient ) to make 200%+ on another share (pos) so added more here and FCS last week

Kidlington etc have been here longer and know their stuff

Please move on as you know nothing and sold last week

Often deals are client confidential but £1.5mln of deals clearly stated in previous RNS

Hepran

PYC has won 4-6 contracts already since the start of the next financial year (July 2023 onwards )and has a pipeline of £1.5mln + we now have Merck resuming with us (annually spend £500k with PYC ) ,

Therefore £8mln cap would still only be about 4 x potential revenues (and that's without any block buster news /partnerships such as the potential £6mln from VAL201)

Amati huge seller out 3mths ago

Tr1 buyers in (see RNSs Last 2mths)

5mln shares issue and only £1.3 cap with £1.9mlnncash as of Sept 2022 and net assets £3mln

Cyber security growth expected

October - Dec 2022 Sales up 44% and same period 2021

, we have several large-scale opportunities advancing with major global technology providers (both new and existing relationships) to partner as part of their Cyber go-to-market plans. As ever these opportunities could be transformational for Falanx

Results for year ended March 2023 published Sept 2023

Perfect time to buy then Noel, £1.2mln cap and looks like Amati we're selling 15-20% of FCS into a direct market hence drop 70p to 20p...Amati were doing this across Aim not just FCS

If you're not invested maybe spend time on yours like DELT ?

Newuncle

Companies release results usually 3mths !AFTER the reporting period and issue trading updates in between, therefore the next OFFICIAL results for the period ending March 2023 is THIS month

Their last trading update and the one from last Sept shows a very good picture

100%+ possible

Annual and recurring revenues up 30%

Final results for the year ended 31 March 2023 FY23 revenue growth and positive EBITDATrading remains robust and in-line with expectations for FY24

You are very welcome,Kidlington is a very informative poster on here

L

AI has also been found to be useful for increasing the chances of a new medicine being successful in treating patients

From PYC website regarding PYC A.I applications

Personalised Dosing Tool Development

Data Identification

Identified public domain data on treatment of prostate cancer using docetaxel for 400+ patients from the comparator arm of a clinical tria

AI & Machine Learning

Applied AI techniques such as neural networks and other machine learning approaches to identify key factors linking dose, toxicity and efficacy

Web-Based Tool

Developed a web-based tool that could, if approved, form the basis of a decision support system for clinicians treating patients with prostate cancer to help reduce cost of toxicity and improve outcomes for patients

Good morning Andy

Personalised medicine is what PYC do ànd is what their dosing tool does (see Januarry 2023 RNS)

They have an A.i/ machine learning dosing tool and the FDA are warning drug conapnies to use these tools if they want to have FDA clearnec e,it is FDA guidelines called Project Optimus

pyc published their findings at the April 2023 AACR and also have their work published in the world famous Frontiers magazine

See below the RNS about about it from April_May 2023

Project Optimus has relevance to Physiomics both in its core consulting business and its personalised oncology initiatives. In core consulting, Project Optimus encourages and some would say even mandates biotech and pharma companies to fully utilise all available non-clinical and clinical data to make informed decisions about clinical trial design and biologically effective dose. The Company believes that there is an increasing expectation that companies meeting with the FDA should have utilised mathematical modelling in support of clinical trial design and dosing decision making. The Company has first hand experience of this through the translational modelling work it has completed for multiple small and medium sized clients in recent years.

 

Looking beyond drug development, the Company sees a clear implication of Project Optimus on dosing of approved drugs in cancer. The vast majority of cancer drugs are still approved on a "one size fits all" basis with, at most, adjustments in dosing being made to account for body weight or surface area of individual patients. The Company believes that the future direction of cancer drug dosing will take into account its effect in each individual and we believe that our personalised dosing tool is a clear step towards achieving that goa

Welcome Nael

Published Dec 2022 for period to Sept 2022and post period of oct-Dec 2022

Early results are promising, with aggregate orders for core services across October and November 2022 growing by 44% compared to the same period in 2021.

 

Outside of our pipeline, we have several large-scale opportunities advancing with major global technology providers (both new and existing relationships) to partner as part of their Cyber go-to-market plans. As ever these opportunities could be transformational for Falanx, and we look forward to updating on these as they progress.